What metrics would you use to evaluate Pear Therapeutics's Somryst prescription digital therapeutic for chronic insomnia?

Introduction

Evaluating the success of Somryst, Pear Therapeutics' prescription digital therapeutic for chronic insomnia, requires a comprehensive approach to product metrics. As a senior product leader, I'll outline a structured framework covering core metrics, supporting indicators, and risk factors while considering all key stakeholders involved in this innovative digital health solution.

Step 1

Product Context

Somryst is a prescription digital therapeutic (PDT) designed to treat chronic insomnia in adults aged 22 and older. It's a software-based intervention that delivers cognitive behavioral therapy for insomnia (CBT-I) through a mobile application. As a PDT, it's regulated by the FDA and requires a prescription from a healthcare provider.

Key stakeholders include:

1. Patients with chronic insomnia
2. Healthcare providers (prescribers)
3. Payers (insurance companies)
4. Pear Therapeutics (the company)
5. Regulatory bodies (FDA)

User flow:

1. Diagnosis and prescription: A healthcare provider diagnoses chronic insomnia and prescribes Somryst.
2. Onboarding: The patient downloads the app and enters their prescription code to activate it.
3. Assessment: The app conducts an initial assessment of the patient's sleep patterns and habits.
4. Treatment: Over 9 weeks, the patient completes 6 CBT-I learning modules and daily sleep diary entries.
5. Follow-up: The app provides ongoing support and allows the patient to track their progress.

Somryst fits into Pear Therapeutics' broader strategy of developing PDTs for various mental health conditions, positioning the company as a leader in the digital therapeutics space. Compared to competitors like Big Health's Sleepio, Somryst's key differentiator is its FDA approval and prescription requirement, potentially increasing its credibility and reimbursement potential.

Product Lifecycle Stage: Somryst is in the growth stage, having received FDA approval in 2020. The focus is on expanding market penetration and gathering real-world evidence of efficacy.

Software-specific context:

• Platform: iOS and Android mobile applications
• Integration points: Electronic Health Records (EHRs) for prescriber workflows, insurance systems for reimbursement
• Deployment model: Direct-to-patient download with prescription activation